Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults

NCT03437304 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

298

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Immunose™ FLU 1%
BIOLOGICAL: Immunose™ FLU 2%, 200 μl
BIOLOGICAL: Immunose™ FLU 2%, 300 μl
BIOLOGICAL: Influenza antigen
DRUG: Placebo
BIOLOGICAL: i.m comparator

Sponsor

Eurocine Vaccines AB